Stockreport

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]

Dyne Therapeutics, Inc.  (DYN) 
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm Check Earnings Report
US:NYSE Investor Relations: dynegy.com/investors/presentations-events
PDF DUBLIN and OXFORD, England April 22, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is p [Read more]